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osting by EAbstract Purpose: To evaluate the short-term safety and efﬁcacy of intravitreal bevacizumab for
the treatment of intraretinal or subretinal ﬂuid accumulation secondary to central serous chorioret-
inopathy (CSC).
Design: Prospective interventional series non-comparative study.
Setting: Department of Ophthalmology, Al-Minya University Faculty of Medicine, Egypt.
Methods: The study included 20 eyes of 20 patients with central serous chorioretinopathy (CSC),
Out of them 10 eyes with acute CSC (group I), 6 eyes with chronic CSC (deﬁned as symptoms pres-
ent for longer than 6 months) and four eyes with recurrent (deﬁned as more than one episode of the
disease) chronic and recurrent cases are considered in one group (group II), all patients were
injected with intravitreal Avastin (IVA) 1.25 mg (0.05 mL) of commercially available bevacizumab
[Avastin; Genentech, Inc., San Francisco, CA] as a primary treatment. At baseline and follow up
visits patients had best corrected visual acuity (BCVA), IOP assessment, dilated fundus examina-
tion, fundus photography, ﬂuorescein angiography (FA) and optical coherence tomography
(OCT) imaging is used for measurement of central retinal thickness (CRT). Main outcome measures
were the resolution of neurosensory detachment, improvement in visual symptoms and visual acu-
ity, and resolution of leakage in FA. Secondary outcome and measures were the need for re-injec-
tion and the adverse effects. The mean number of injections was 2 (range 1–3 injections) 6–8 weeks. Abdulrahman Al-Mishary
, Saudi Arabia. Tel.: +966 01
com (S.A. Mehany).
ity. All rights reserved. Peer-
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70 S.A. Mehany et al.intervals and follow up for 6 months (range 5–7 months). All ﬁnding at baseline and each follow up
visit were reported and compared.
Results: The mean age of all patients was 40.3 years ± 6.5 (range 25–50 years), 15 males and ﬁve
females patients. In acute CSC group, the mean baseline BCVA was 20/60 (log MAR 0.48) and
improved to 20/30 (log MAR 0.18) with statistically signiﬁcance difference change (P< 0.003)
and in (chronic and recurrent group), the mean baseline VA was 20/80 (log MAR 0.60) and
improved to 20/40 (log MAR 0.30) with statistically signiﬁcance difference change (P< 0.002).
The mean baseline CRT for all patients was 486 ± 86 lm (range, 386–580), decreased to
316 ± 56 lm (range, 276–368) after 1 months with statistically signiﬁcance difference change
(P< 0.02) and to 272 ± 52 lm (range 220–338) at last follow up with statistically signiﬁcance dif-
ference change from the baseline (P< 0.001).
Conclusions: Intravitreal Avastin (IVA) injection was associated with visual improvement and
reduced neurosensory detachment without adverse events in patients with CSC. Although these
results are promising, further randomized controlled studies would be helpful to understand this
therapy for patients with CSC.
ª 2010 King Saud University. All rights reserved.1. Introduction
Central serous chorioretinopathy (CSC) is a disease of young
and middle-aged adults as a localized detachment of the neu-
rosensory retina. It frequently manifests symptomatically in
one eye, while up to 18% of cases may be bilateral. Research
indicates that the disease process in CSC is more diffuse and
shows bilateral retinochoroidal dysfunction, even when the
disease is manifesting clinically only in one eye. Though the
cause of CSC remains unknown, it is believed that abnormal-
ities in choroidal circulation make overlying retinal pigment
epithelium dysfunctional, resulting in the development of a ser-
ous retinal detachment. Photodynamic therapy, laser photoco-
agulation and pharmacological agents (Acetazolamide,
propanolol, Mifepristone and Ketoconazole) have been used
to treat CSC. However, these treatment options serve only to
shorten the duration of symptoms and have no effect on the
recurrence rate or the ﬁnal visual acuity (Schaal et al., 2009).
In cases with chronic diffuse or persistent focal leakage, retinal
pigment epithelium (RPE) may decompensate leading to grad-
ual visual loss with a less favorable visual prognosis (Jalk et al.,
1984; Loo et al., 2002).
Type A personalities, systemic hypertension, and obstruc-
tive sleep apnea may be associated with CSC. The pathogene-
sis here is thought to be elevated circulating cortisol and
epinephrine, which affect the autoregulation of the choroidal
circulation. Furthermore, (Tewari et al., 2006), demonstrated
that patients with CSC showed impaired autonomic response
with signiﬁcantly decreased parasympathetic activity and sig-
niﬁcantly increased sympathetic activity. Corticosteroids have
a direct inﬂuence on the expression of adrenergic receptor
genes and, thus, contribute to the overall effect of catechola-
mines on the pathogenesis of CSC. Consequently, multiple
studies have conclusively implicated the effect of corticoste-
roids in the development of CSC. Carvalho-Recchia et al.
(2002) showed in a series that 52% of patients with CSC had
used exogenous steroids within 1 month of presentation as
compared with 18% of control subjects.
Cotticelli et al. (2006) showed an association between Hel-
icobacter pylori infection and CSC. The prevalence ofH. pylori
infection was 78% in patients with CSC compared with a prev-
alence of 43.5% in the control group. The authors proposedthat H. pylori infection may represent a risk factor in CSC,
though no further studies have substantiated this claim. CSC
is not a benign disease, as RPE atrophy and associated visual
loss in chronic or persistent cases is slow but continuous pro-
cess (Jalk et al., 1984).
Cardillo Piccolino et al. (1995), reported by indocyanine
green (ICG) angiography, primary choroidal involvement in
CSC, consisting of areas of choroidal vascular hyperperme-
ability and hence leakage in the RPE and RPE decompensa-
tion. On the basis of this knowledge, it seems reasonable to
target the choroidal vascular changes with new strategies to
treat CSC.
This study was performed to evaluate the short-term safety
and efﬁcacy of IVA for the treatment of intraretinal or subret-
inal ﬂuid accumulation secondary to different forms of CSC.
2. Patients and methods
This prospective interventional series non-comparative study
included 20 eyes of 20 patients with CSC, 10 eyes (50%) had
acute CSC and six eyes (30%) had chronic CSC (deﬁned as
symptoms present for longer than 6 months) and four eyes
(20%) with recurrent (deﬁned as more than one episode of the
disease). Inclusion criteria including; documented subfoveal
ﬂuid by OCT, active leak associated with the subfoveal ﬂuid,
the ability and willingness to provide written informed consent,
no signs of choroidal neovascularization. Exclusion criteria
including; prior treatment with laser photocoagulation, TTT
(transpupillary thermotherapy) or PDT (photodynamic ther-
apy), have a history of thromboembolic events including stroke,
transient ischemic attacks, and myocardial infarction, IVT
(intravitreal triamcinolone) or bevacizumab in the previous
2 months, uncontrolled glaucoma (IOP>24 mm Hg) on great-
er than three medications, visual acuity of worse than 20/400 in
the fellow eye, unable to follow or comply with all study related
procedures, have uncontrolled hypertension, previously vitrec-
tomized eyes or had allergic reactions to ﬂuorescein dye. All eyes
were injected with intravitreal Avastin (IVA) 1.25 mg (0.05 mL)
of commercially available bevacizumab [Avastin; Genentech,
Inc., San Francisco, CA] at a concentration of 25 mg/mL.
At baseline and follow up visits patients had measured best
corrected visual acuity (BCVA), IOP assessment, dilated fun-
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diopters lenses, fundus photography, ﬂuorescein angiography
(FA) and optical coherence tomography (OCT) imaging is
used for measurement of central retinal thickness (CRT). Main
outcome measures were the resolution of neurosensory detach-
ment, improvement in visual symptoms and visual acuity, and
resolution of leakage in FA. Secondary outcome measures
were the need for re-injection and the adverse effects. Optical
coherence tomography (OCT) was performed for all of pa-
tients. Stratus OCT3, (Carl Zeiss Meditec, Dublin, CA). Read-
ings for 1 mm central retinal thickness (CRT) were obtained
from the mean retinal thickness in the central subﬁeld using
six linear scans 6 mm long centered on ﬁxation and processed
as a retinal map.
In all patients, the intravitreal injection of off label bev-
acizumab was performed in a standard protocol in the operat-
ing theater under operating ophthalmoscope and complete
aseptic condition after obtaining informed consent. Topical
0.4% Benoxinate hydrochloride was applied to the ocular sur-
face followed by scrubbing of the eye lids and lashes with 10%
of Povidone iodine and conjunctiva installed with 5% Povi-
done iodine three times several minutes apart. A sterile eyelid
speculum was used for all injections, sub-conjunctival 1 cc
Lidocaine 2% was done at the site of bevacizumab injection
in the inferotemporal quadrant. Bevacizumab was injected
through the pars plana 3.5–4.0 mm posterior to the surgical
limbus using a 30-gauge needle at a dose of 1.25 mg in
0.05 mL. Post injection, a sterile cotton swab is placed at the
site of injection to prevent reﬂux of vitreous or drug, light per-
ception was assessed and indirect ophthalmoscope to see optic
nerve head perfusion.
After the injection, the patients were instructed to apply
topical antibiotics to the injected eye four times a day for
5 days. Postoperative follow up included repeated clinical
examinations and OCT to all of the patients. Patients were as-
sessed for adverse events including elevated intraocular pres-
sure, cataract progression, retinal detachment, post-injection
inﬂammation, and endophthalmitis. Follow up evaluations
were scheduled to next day, 1 week then monthly till the end
of follow up. Repeated FA and OCT were done at 1 month,
3 months and at the end of follow up, about 6 months. A re-
peated injection of bevacizumab was performed for persistent
or recurrent CSC seen by ﬂuorescein angiography and docu-
mented by OCT imaging.
The main outcome included resolution of leakage in FA,
changes in CRT using OCT and changes in BCVA. Secondary
outcome included any systemic or ocular adverse effects of
IVA injection and the need for repeated injections. Snellen’s
BCVA were converted to logarithmic minimum angle of reso-
lution (log MAR) for statistical analysis. Statistical analysis
was assessed using (SPSS, version 13, SPSS Inc., Chicago, Illi-Table 1 Mean CRT and mean BCVA at baseline and follow up.
Timing Mean (SD) {range} CMT (lm) Dif. CMT (lm)
Baseline 486 (±86) {386–580}
1 month 316 (±56) {276–368} 170
3 months 325 (±76) {288–380} 161
6 months 272 (±52) {220–338} 214
P value considered to be statistically signiﬁcant if it is <0.05.nois, USA). All variables were expressed as mean ± standard
deviation (SD), the paired Student t-test was used and P value
60.05 was considered statistically signiﬁcant.
3. Results
In this prospective study, 20 eyes of 20 patients received intra-
vetrial Avastin (IVA) injection. Out of them 10 eyes (50%)
with acute CSC (group I) and six eyes (30%) with chronic
CSC (deﬁned as symptoms present for longer than 6 months)
and four eyes (20%) with recurrent (deﬁned as more than
one episode of the disease), chronic and recurrent eyes with
CSC considered in one group (group II). The mean age of
all patients was 40.3 years ±6.5 (range 25–50 years), 15 males
and ﬁve females patients. Fourteen patients (70%) out of all
patients demonstrated positive (HP) H. pylori infection. No
one had history of recent corticosteroid therapy. The mean fol-
low up period was 6 months (range, 5–7 months).
In acute CSC group, the mean baseline BCVA was 20/60
(log MAR 0.48) and improved to 20/30 (log MAR 0.18) at
the end of follow up with statistically signiﬁcance difference
change (P< 0.003) and in (chronic and recurrent group),
the mean baseline VA was 20/80 (log MAR 0.60) and im-
proved to 20/40 (log MAR 0.30) at last follow up with statis-
tically signiﬁcance difference change (P< 0.003). The overall
mean of BCVA of all cases at baseline was 20/70 (log MAR
0.54) and improved to 20/35 (log MAR 0.24) at last follow
up with statistically signiﬁcance difference change
(P< 0.002) as shown in Table 1. All of eyes had visual
improvement, 14 eyes (70%) had gained two or more lines
improvement in BCVA at the end of follow up. None of eyes
had decreased vision than the baseline BCVA.
There was decrease in the mean of CRT all over the time
which was correlated with the improvement in both of BCVA
and FA leakage. The mean baseline CRT for all patients was
486 ± 86 lm (range, 386–580), decreased to 316 ± 56 lm
(range, 276–368) after 1 months with statistically signiﬁcance
difference change (P< 0.02) and difference of 170 lm from
baseline CRT and to 325 ± 76 lm (range, 288–380) after
3 months with a difference of 161 lm and to 272 ± 52 lm
(range 220–338) at last follow up with statistically signiﬁcance
difference change from the baseline (P< 0.001) in which the
difference was 214 lm as shown in Table 1.
There was complete resolution of ﬂuorescein leakage after
one injection in eight eyes (40%) of all patients within 2 weeks,
out of them ﬁve eyes in group I and three eyes in group II.
Twelve eyes (60%) had not resolved completely by one injection
and needs re-injection or recurrence and re-injection was done.
However, the leakage in recurrent eyes was with less severity
than that of the baseline. Six eyes in group II and two eyes in
group I need three IVA injections as demonstrated in Table 2.P value Mean BCVA Log MAR (SD) P value
20/70 0.54 (±0.25)
<0.02 20/50 0.35 (±0.17) <0.01
<0.02 20/50 0.35 (±0.17) <0.01
<0.001 20/35 0.24 (±0.18) <0.003
Table 2 Mean, number of injections for each eye.
Number of
injections
10 Eyes of
group (I) CSC
10 Eyes of
group (II) CSC
Total number
of eyes (%)
One injection 5 3 8 (40%)
Two injections 3 1 4 (20%)
Three injections 2 6 8 (40%)
Total number of
injection, (mean)
17, (1.7) 23, (2.3) 40, (2)
72 S.A. Mehany et al.Table 2 reported the mean number of IVA injection for all
patients, it was 2 (range, 1–3), 6–8 week interval for re-injec-
tion and the total number of injections are 40 injections for
20 eyes. It was a little bit higher in group II in which it was
(2.3), 23 injections for 10 eyes and a little bit less in group I
in which it was (1.7), 17 injections for 10 eyes. There were 14
patients (70%) out of all patients’ demonstrated positive
(HP) H. pylori infection by serum antibody titer and some-
times by urea breath test when available. There were neither
systemic nor intraocular adverse effects seen in our study ex-
cept some sort of sub-conjunctival hemorrhage at the site of
injection resolved spontaneously with time in three patients.
4. Discussion
Central serous chorioretinopathy (CSC) is a disease in which a
serous detachment of the neurosensory retina occurs over an
area of leakage from the choriocapillaris through the retinal
pigment epithelium (RPE). CSC may be divided into two dis-
tinct clinical presentations. Classically, acute CSC is caused by
one or more discrete isolated leaks at the level of the RPE as
seen on ﬂuorescein angiography (FA). However, it is now rec-
ognized that CSC may present with diffuse retinal pigment epi-
thelial dysfunction (e.g. diffuse retinal pigment epitheliopathy,Figure 1 (A) Colored fundus photography of Rt. acute CSC at base
and subretinal ﬂuid and increased CRT= 480 lm at baseline. (C) O
subretinal ﬂuid and decreased CRT = 280 lm after 1 month of IVA in
subretinal ﬂuid and decreased CRT = 240 lm after 1 month of the sechronic CSC, decompensated RPE) characterized by neuro-
sensory retinal detachment overlying areas of RPE atrophy
and pigment mottling. During FA, broad areas of granular
hyperﬂuorescence that contain one or many decompensatory
leaks are seen as in Fig. 3B. Previous hypotheses for the path-
ophysiology have included abnormal ion transport across the
RPE and focal choroidal vasculopathy. The advent of indocy-
anine green (ICG) angiography has highlighted the importance
of the choroidal circulation to the pathogenesis of CSC. ICG
angiography has demonstrated both multifocal choroidal
hyperpermeability and hypoﬂuorescent areas suggestive of fo-
cal choroidal vascular compromise. Some investigators believe
that initial choroidal vascular compromise subsequently leads
to secondary dysfunction of the overlying RPE (Schaal et al.,
2009).
Chappelow and Marmor (2000) reported in their study
using multifocal electroretinography that CSC patients had
bilateral diffuse retinal dysfunction even when CSC was active
only in one eye and diminished response amplitudes even after
complete absorption of subretinal ﬂuid. These studies support
the belief of diffuse systemic effect on the choroidal vascula-
ture. Wang et al. (2002) reported that foveal atrophy in CSC
is associated with reduction of visual acuity despite resolution
of serous detachment and hence reattachment within 4 months
of onset is considered a relevant therapeutic target because
prolonged detachment is associated with photoreceptor atro-
phy. Stewart (2006) reported that the fact that laser damages
the RPE with a known risk of developing choroidal neovascu-
larization (CNV) has left clinicians seeking new treatments
that are both more effective and less toxic. Without prior
ICG dye, investigators have also used the 810 nm laser as
transpupillary thermotherapy (TTT) with moderate anecdotal
success. However, Penha et al. (2007) described severe retinal
thermal injury in a 31-year-old man following this treatment
modality and recommended caution for this adverse event fol-
lowing ICG mediated TTT treatment.line. (B) OCT of the same patient with sensory retinal detachment
CT of the same patient with incomplete or partial resolution of
jection. (D) OCT of the same patient with complete resolution of
cond IVA injection at the end of follow up.
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guided by ICG angiography and performed according to the
protocol of the TAP Study seems to resolve macular detach-
ment, serous exudation and preserve visual acuity in patients
with chronic CSC. PDT could reduce choriocapillaris blood
ﬂow and choroidal exudation in the areas of subretinal ﬂuid
production. However, undesired effects are pigmentary
changes in the treatment zone and persistent hypoperfusion
of the choriocapillaris. Chan et al. (2003), reported develop-
ment of CNV within the photodynamic zone due to localized
ischemia in choriocapillaries secondary to PDT in chronic
CSC patients with unhealthy RPE.
In our study IVA was used for treatment of different forms
of CSC patients as shown in Figs. 1–4 and had good results in-
spit of there is no direct evidence for vascular endothelial
growth factor (VEGF) in inducing CSC. Shams and Ianchulev
(2006), reported that VEGF is a critical regulator of ocular
angiogenesis and vascular permeability. When increased cho-
roidal hyperpermeability claimed to be one of the main under-
lying mechanisms of CSC, it seemed logic to treat such cases
with anti-VEGF such as (Avastin, Genentech, Inc., San Fran-
cisco, CA), a full-length recombinant monoclonal antibody
against human vascular endothelial growth factor which was
approved by the food and drug administration for treatment
of colorectal cancer and used to treat different ocular diseases
on off label basis with informed consent of patients.
In the current study, 14 patients (70%) out of all patients
demonstrated positive (HP) H. pylori infection and this inFigure 3 (A) Colored fundus photography of Lt., eye with chronic
showing granular hyperﬂuorescence with many decompensatory leaks a
case with fading in late stage.
Figure 2 Colored fundus photography of Rt., eye with recurrent
CSC at baseline, subretinal ﬂuid was turbid.agreement with the results of (Cotticelli et al., 2006), in which
they reported an association between H. pylori infection and
CSC, the prevalence ofH. pylori infection was 78% in patients
with CSC compared with a prevalence of 43.5% in the control
group. Our result as well as that of the previous mentioned
study in this point draws our attention to thoroughly investi-
gate all patients of CSC for (HP) infection and to treat positive
cases with proper medical treatment. As shown in Fig. 6, the
overall mean of BCVA in our study improved from 20/70 at
baseline to 20/50 after one month and stayed stationary for
the third month after IVA injection (1.25 mg) then improved
more to 20/35 after 6 months due to complete resolution of
some cases in which it was previously had partial resolution
as in Fig. 1C or recurrence and improved by re-injection as
only 40% of patients had complete resolution after one IVA
injection. Resolution and improvement of vision depend on
the viscosity of subretinal ﬂuid, duration of the disease and
amount of photoreceptor damage. However all of eyes had vi-
sual improvement and 70% of patients had gained two or
more lines improvement than the baseline. There was decreaseCSC showing RPE atrophy at baseline. (B) FA, of the same case
nd two macular leaking spots in venous phase. (C) FA of the same
Figure 4 (A) FA, of acute case of CSC with active central
leaking hyperﬂuorescent spot. (B) FA, of the same case with
enlargement of the leaking spot. (C) FA, of the same case with
more leaking, enlargement and smoke stack formation. (D) FA, of
the same case with resolution of the leaking spot after 2 weeks of
IVA injection.
Figure 5 Graph for CRT over follow up time.
74 S.A. Mehany et al.in the mean of CRT all over the time which was correlated
with the improvement in both of BCVA and FA leakage.
The mean baseline CRT for all patients was 486 ± 86 lm
(range, 386–580), decreased to 272 ± 52 lm (range 220–338)
at last follow up with statistically signiﬁcance difference
change from the baseline (P< 0.001) in which the difference
was 214 lm as demonstrated in Fig. 5.
Our result in agreement with (Torres-Soriano et al., 2008),
they reported in a study of six eyes (ﬁve chronic and one recur-
rent CSC) that visual acuity improved in all cases by 1 month
after treatment (IVA injection) and remained stable until the
examination at the third month, she said that the median best
corrected visual acuity in her study improved from 20/200 at
baseline to 20/100 at 1 month and 20/50 at 3 months. They ob-
served decreased neurosensory retinal and retinal pigment epi-
thelial detachment on OCT. The retinal thickness decreasedFigure 6 Graph for BCVfrom 375.83 ± 92.34 lm to 252.5 ± 58.28 lm at 1 month
and 223 ± 69.5 lm at 3 months post-treatment. There was a
decrease in ﬂuorescein leakage and improved choroidal hyper-
permeability seen on indocyanine green angiography. Two
eyes (1/3 of patients) required a second injection of bev-
acizumab, Dr. Torres-Soriano commented. No adverse events
developed. However, they used higher concentration dose of
Avastin (2.5 mg).
Also our results in agreement with (Seong et al., 2009), in
which they reported in a series of 10 eyes of 10 patients with
acute CSC that all patients showed resolution of neurosensory
detachment promptly, and improvement in visual acuity and
symptoms within 1 month. At 6 months the mean BCVA
(log MAR) had improved from 0.32 to 0.04, which was statis-
tically signiﬁcant (P= 0.007). No recurrence was observed
during the 6 months follow up.A over follow up time.
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et al., 2009), they studied 12 eyes with chronic CSC in which
patients received 2 ± 1 intravitreal injections of bevacizumab
2.5 mg on average during a follow up of 24 ± 14 weeks. Mean
BCVA increased by 2 ± 2 lines; the change in BCVA (log
MAR) was signiﬁcant (P< 0.02). Mean central retinal thick-
ness decreased signiﬁcantly over follow up (P< 0.05), with
six patients (50%) showing complete resolution of subretinal
ﬂuid. Also in agreement with (El-Batarny et al., 2008), in their
study of effect of one injection 1.25 mg dose of IVA in 10 cases
of chronic and persistent CSC, they concluded that 90% of pa-
tients had visual improvement. Six eyes (60%) gained two or
more lines in BCVA at last follow up. The mean log MAR
of BCVA improved from 0.50 ± 0.25 at baseline to 0.11 ±
0.16 at last follow up (P= 0.003). Complete resolution was
achieved in 60% of cases and CMT improved from 483.6 ±
73 lm (range, 632–412) at baseline to 274.6 ± 104 lm (range,
440–162) at last follow up with statistically signiﬁcant differ-
ence (P= 0.001).
Our results conclude that anatomic and functional
improvement following intravitreal Avastin injections suggest
that vascular endothelial growth factor (VEGF) may be in-
volved in ﬂuid leakage in patients with CSC. This is consistent
with the previous studies that found that Avastin was effective
in the treatment of different forms of CSC and resolution of
subretinal ﬂuid due to decreased choroidal hyperpermeability
after IVA injection which it was proven to be markedly in-
creased in cases of CSC. The results suggest a possible role
for anti-VEGF agents in the treatment of CSC. Further eval-
uation of intravitreal Avastin for CSC patients in controlled
randomized large number of patients with longer follow up
period are necessary to conﬁrm the efﬁcacy and safety of bev-
acizumab and to determine the ideal protocol for this new
promising treatment.
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